Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma

References

• American Cancer Society. Cancer facts and figures 2010. Atlanta, GA: ACS. 2010. Available from: http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf
   Google Scholar
• The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89: 3909–3918.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780–2795.
   PubMed Web of Science ®Google Scholar
• The Non-Hodgkin's Lymphoma Classification Project. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol 1997;8:973–978.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346: 235–242.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, . Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7: 379–391.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Smith P, Mouncey P, . A phase III trial comparing R-CHOP 14 to R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell lymphoma. J Clin Oncol 2009;27(Suppl.): Abstract 8506.
   Google Scholar
• Zinzani PL, Rossi G, Franceschetti S, . Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res 2010;16:3998–4004.
   PubMed Web of Science ®Google Scholar
• Karmali R, Manson A, Venugopal P, . Phase II study of 2-weekly CHOP + rituximab followed by yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): final analysis. Blood 2010;116(Suppl. 1): Abstract 3947.
   Google Scholar
• Coiffier B. Standard treatment of advanced-stage diffuse large B-cell lymphoma. Semin Hematol 2006;43:213–220.
   PubMed Web of Science ®Google Scholar
• Coiffier B. Treatment of non-Hodgkin's lymphoma: a look over the past decade. Clin Lymphoma Myeloma 2006;7(Suppl. 1): S7–S13.
   PubMedGoogle Scholar
• Lenz G, Dreyling M, Hoster E, . Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984–1992.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Khouri IF, Kantarjian HM, . Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 2000;39:77–85.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad L, Feng L, . Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and witout stem-cell transplantation in patient with untreated aggressive mantle-cell lymphoma. Br J Haem 2010; 150:200–208.
   PubMed Web of Science ®Google Scholar
• Kahl B, Li H, Smith MR, . The VcR-CVAD regimen produces high complete response rate in untreated mantle cell lymphoma (MCL): first analysis of E1405--a phase II study of VcR-CVAD with maintenance rituximab for MCL. Blood 2009;114(Suppl. 1): Abstract 1661.
   Google Scholar
• Rummel ML, Niederle N, Maschmeyer G, . Bendamustine plus rituximab is superior in respect to progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment for patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009;114(Suppl. 1): Abstract 405.
   Google Scholar
• Geisler C. Front-line treatment of mantle cell lymphoma. Haematologica 2010;95:1241–1243.
   PubMed Web of Science ®Google Scholar
• Balducci L, Carreca I. The role of myelopoietic growth factors in managing cancer in the elderly. Drugs 2002;62(Suppl. 1): S47–S63.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Reiser M, Schwarzer G, . Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haem 2003;122:413–423.
   PubMed Web of Science ®Google Scholar
• Gomez H, Mas L, Casanova L, . Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998;16:2352–2358.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Venugopal P, Kern JC, . GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas. Leuk Lymphoma 2008;49: 1681–1692.
   PubMed Web of Science ®Google Scholar
• Venugopal P, Sivaraman S, Preisler HD, . Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res 2000;24:411–415.
   PubMed Web of Science ®Google Scholar
• Vose JM, Link BK, Grossbard ML, . Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389–397.
   PubMed Web of Science ®Google Scholar
• Vose JM, Link BK, Grossbard ML, . Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2005;46:1569–1573.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thielblemont C, Van Den Neste E, . Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de L'Adulte. Blood 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Gazitt Y, Shaughnessy P, Devore P. Mobilization of dendritic cells and NK cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 2001;10: 177–186.
   PubMedGoogle Scholar
• Morrissey PJ, Bressler L, Park LS, . Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol 1987;139:1113–1119.
   PubMed Web of Science ®Google Scholar
• Young DA, Lowe LD, Clark SC. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity. J Immunol 1990;145:607–615.
   PubMed Web of Science ®Google Scholar
• Eisenbeis CF, Grainger A, Fischer B, . Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase study. Clin Cancer Res 2004;10:6101–6110.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Neuberg D, Gribben JG, . Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haem 2002;117:828–834.
   PubMed Web of Science ®Google Scholar
• Banks RE, Patel PM, Selby PJ. Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer 1995;71:655–659.
   PubMed Web of Science ®Google Scholar
• Younes A, Pro B, Robertson MJ, . Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 2004;10:5432–5438.
   PubMed Web of Science ®Google Scholar
• Andorsky DJ, Timmerman JM. Interleukin-21: biology and application to cancer therapy. Expert Opin Biol Ther 2008;8: 1295–1307.
   PubMed Web of Science ®Google Scholar
• Kimby E, Jurlander J, Geisler C, . Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma 2008;49:102–112.
   PubMed Web of Science ®Google Scholar
• Decker T, Schneller F, Sparwasser T, . Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000;95:999–1006.
   PubMed Web of Science ®Google Scholar
• Jahrsdorfer B, Hartmann G, Racila E, . CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001;69:81–88.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Kim H, McCauley M, . Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005;105:489–495.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Link BK, Emmanouilides C, . Phase I trial of Toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-Hodgkin's lymphoma. Clin Cancer Res 2007;13: 6168–6174.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Kelly JL, Neuberg D, . Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 2009;146:282–291.
   PubMed Web of Science ®Google Scholar
• Chang JE, Seo S, Kim KM, . Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study. Clin Lymphoma Myeloma Leuk 2010;10:379–384.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Liu N, Poindexter N, . Rituximab plus GM-CSF (Leukine) for indolent lymphoma. Ann Oncol 2005;16(Suppl. 5): Abstract 104.
   Google Scholar
• Cartron G, Zhao-Yang L, Baudard M, . Granulocyte-macrophase colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol 2008;26:2725–2731.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, O'Brien SM, Faderl SH, . The combination of rituximab and GMCSF in elderly patients with chronic lymphocytic leukemia (CLL). J Clin Oncol 2006;24(Suppl.): Abstract 6602.
   Google Scholar
• Ferrajioli A. Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2009;50: 514–516.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Meisenberg B, Sarkodee-Adoo C, . Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 2002;29:303–312.
   PubMed Web of Science ®Google Scholar
• Olivieri A, Lucesole M, Capelli D, . A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biol Blood Marrow Transplant 2005;11:627–636.
   PubMed Web of Science ®Google Scholar
• Brusamolino E, Rusconi C, Montalbetti L, . Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006;91:496–502.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Feugier P, Mounier N, . Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. J Clin Oncol 2007;25(18 Suppl.): Abstract 8009.
   Google Scholar
• Cunningham D, Smith P, Mouncey P, . A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009;27(Suppl.): Abstract 8506.
   Google Scholar
• Cunningham S, Muneer S, Aarati R, . The 51st Annual Meeting of the American Society of Hematology. Clinc Lymphoma Myeloma Leuk 2010;10:11–20.
   PubMedGoogle Scholar
• Mikhaeel NG, Timothy AR, Hain SF, . 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000;11(Suppl. 1):147–150.
   PubMed Web of Science ®Google Scholar